-
Toremifene in Prostate Cancer Assay Design
2026-09-15
Toremifene offers a focused way to study estrogen receptor modulation alongside metastatic prostate cancer biology. This article develops an assay-centered framework linking hormone-responsive phenotypes with the TSPAN18–STIM1 calcium-signaling mechanism while clearly separating evidence from testable hypotheses.
-
Rotigotine in Depression and PD Research
2026-09-15
Rotigotine is a dopamine D2/D3 receptor agonist with applications extending from Parkinson’s disease models to depression phenotyping. This article interprets behavioral endpoints, dose-dependent locomotor confounding, and assay-design implications beyond conventional neuroprotection workflows.
-
OSMI-1: O-GlcNAc Transferase Inhibitor Workflows
2026-09-14
OSMI-1 provides a cell-permeable loss-of-function approach for connecting OGT activity with protein modification, iron handling, ferroptosis, and trophoblast syncytialization. This workflow-focused guide explains how to establish target engagement, separate pathway effects from cytotoxicity, and interpret results in the context of preeclampsia research.
-
Toremifene in Prostate Cancer Research
2026-09-14
Toremifene is a second-generation selective estrogen-receptor modulator used in research on estrogen receptor signaling, hormone-responsive cancer biology, and prostate cancer models. Product information reports an approximate in vitro Ac-1 cell-growth IC50 of 1 ± 0.3 μM, while peer-reviewed work identifies the STIM1-Ca2+ axis as a bone-metastasis mechanism that remains to be tested directly with Toremifene.
-
Tau p-Ser356 in Alzheimer’s Disease and NUAK Inhibition
2026-09-13
Taylor et al. characterize tau phosphorylated at serine 356 as a pathology-associated species that increases with Alzheimer’s disease progression and localizes to neurofibrillary tangles and synapses. Their ex vivo experiments further show that NUAK inhibition produces tissue-dependent effects: broad tau and synaptic protein loss in mouse slices but more selective p-tau Ser356 reduction in human brain slices.
-
Dextrose (D-Glucose) as a Metabolic Control Variable
2026-09-12
Dextrose (D-glucose) is more than a routine nutrient: it is a controllable variable for resolving nutrient competition, hypoxia, and cellular energy production. This guide connects product quality and handling with assay architecture for glucose metabolism research, tumor immunometabolism, and related cell studies.
-
Tuning Stem Cell Fate with CHIR 99021
2026-09-11
CHIR 99021 trihydrochloride is more than a potent GSK-3 inhibitor: it is a controllable experimental input for connecting stemness, differentiation, organoid scalability, and metabolic research. This thought-leadership article interprets the tunable human intestinal organoid study through a translational lens, while defining practical validation strategies, limitations, and opportunities for CHIR-based experimental design.
-
Toremifene in Prostate Cancer Research
2026-09-11
Toremifene is a second-generation selective estrogen-receptor modulator used to study estrogen receptor signaling and hormone-responsive cancer biology. Product data report an in vitro cell growth inhibition benchmark of approximately 1 ± 0.3 μM in Ac-1 cells, while prostate cancer metastasis research identifies the TSPAN18–STIM1–TRIM32 axis as a separate calcium-signaling framework for mechanistic comparison.
-
VX-702 and the Next Era of p38α MAPK Research
2026-09-10
VX-702 offers translational researchers a selective, ATP-competitive route to interrogate p38α MAPK signaling, connect cytokine biology with tissue outcomes, and test how kinase conformation may shape phosphatase-mediated pathway shutdown.
-
ddATP Workflows for DNA Synthesis Termination
2026-09-10
Learn how ddATP converts nucleotide incorporation into a controllable endpoint for Sanger sequencing, PCR termination assays, enzyme studies, and DNA-repair research. This workflow-focused guide translates evidence from mouse-oocyte ssBIR research into practical controls, dose-finding strategies, and troubleshooting decisions.
-
ATS-9R/siCcl2 Targeting of ATMs in GDM
2026-09-09
The reference study developed an ATS-9R/siCcl2 complex to suppress CCL2 in adipose tissue macrophages and investigated its effects on inflammation and insulin resistance in gestational diabetes mellitus. Its main contribution is a cell- and tissue-directed, non-viral gene-silencing strategy that links ATM inflammation with calcium dysregulation, mitochondrial oxidative stress, and metabolic impairment.
-
C34 TLR4 Inhibitor: Assay Workflow Guide
2026-09-09
C34 enables selective interrogation of TLR4-driven inflammation in macrophage, enterocyte, and microglial models without treating broad inflammatory suppression as target validation. This workflow guide translates reference-study findings into practical dosing, controls, troubleshooting, and translational assay choices.
-
ATG9A, PTOV1, and 14-3-3 Cancer Mechanisms
2026-09-08
The reference study identifies ATG9A and PTOV1 as previously unrecognized 14-3-3-interacting proteins and defines distinct mechanisms linking them to basal autophagy and oncogenic signaling. Its combination of proximity labeling, quantitative proteomics, and biochemical validation provides a useful framework for interpreting regulated protein stability, trafficking, and degradation in cancer biology.
-
Meropenem Trihydrate for Resistance Research
2026-09-08
Meropenem trihydrate is a broad-spectrum carbapenem antibiotic used to investigate bacterial cell wall inhibition, antimicrobial activity, and resistance phenotypes. The 2025 reference study shows that LC-MS/MS metabolomics distinguished carbapenemase-producing Enterobacterales from non-producing isolates in under 7 hours, but the assay was a resistance-detection workflow rather than a meropenem susceptibility test.
-
AL-8810: A Causal Map of FP Signaling
2026-09-07
AL-8810 is a prostaglandin F2α antagonist suited to receptor-level analysis of PGF2α responses. This article develops a causal assay framework linking FP receptor pharmacology with ERK1/2, MMP-2, vascular, and endometrial readouts while distinguishing established evidence from experimental strategy.